Novel genetic approaches to study breast cancer

Projektinformationen

NOVEL BREAST CANCER

ID Finanzhilfevereinbarung: 509666

Startdatum 1 Juni 2004

Enddatum 31 Oktober 2008

Finanziert unter

• Human resources and Mobility in the specific programme for research, technological development and demonstration "Structuring the European Research Area" under the Sixth Framework Programme 2002-2006

Gesamtkosten € 0,00

EU-Beitrag € 1 864 167,00

Koordiniert durch

INSTITUTE OF MOLECULAR BIOTECHNOLOGY OF THE AUSTRIAN ACADEMY OF SCIENCES
Austria

Ziel

The genetic code of humans and multiple other species has been identified. The critical experiments will be to identify the function of these genes in normal physiology and in diseases such as cancer. Genetic animal models have proven to be extremely valuable to elucidate the essential functions of genes.

In particular, the generation of transgenic mice and so-called gene targeted mice has provided novel insights into gene functions and the pathogenesis of disease. Using gene-targeted mice Penninger's group has identified a master gene, RANKL, of bone loss in arthritis and osteoporosis (Nature, 1999; Nature 1999; Cell 2000) and they identified genes that control heart size (Nature 2002;Cell 2002); cell death (Nature 1999 & 2001); cancer (Nature 2000); or pain (Cell 2002).

Based on impact factors, his laboratory has been ranked as one of the 10 best laboratories in the world as the only non-US based research group and Prof. Penninger was ranked among the 10 most promising young scientists in the world in all fields of Sciences. After 13 years in North America, the Austrian Academy of Sciences has now made Prof. Penninger and his group an offer to come to Vienna to continue his outstanding work at IMBA, a new Centre of Excellence founded by the Austrian Academy of Sciences.

Cancer care will be revolutionized over the next decade by the introduction of novel therapeutics that target the underlying molecular mechanisms of the disease. Prof. Penninger will bring his expertise in functional mouse genomics and biochemistry to Europe to create a new European centre of excellence.

A primary goal is to generate a platform for the development and application of functional genomics in order to understand the pathogenesis of malignancies and to provide new animals models to test and develop novel therapies.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › oncology › prostate cancer
• medical and health sciences › clinical medicine › rheumatology
• medical and health sciences › clinical medicine › oncology › breast cancer
• medical and health sciences › basic medicine › physiology
• medical and health sciences › basic medicine › medical genetics

Schlüsselbegriffe

• Gene targeting
• RNAi
• breast cancer
• cancer
• cancer metastasis
• fly genetics
• oncogenes

Programm/Programme

• FP6-MOBILITY - Human resources and Mobility in the specific programme for research, technological development and demonstration "Structuring the European Research Area" under the Sixth Framework Programme 2002-2006

Thema/Themen

• MOBILITY-3.1 - Marie Curie Excellence Grants (EXT)

Aufforderung zur Vorschlagseinreichung

FP6-2002-MOBILITY-8
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

EXT - Marie Curie actions-Grants for Excellent Teams

Koordinator

INSTITUTE OF MOLECULAR BIOTECHNOLOGY OF THE AUSTRIAN ACADEMY OF SCIENCES

• EU-Beitrag: Keine Daten
• Adresse: Dr. Bohrgasse 7 ; VIENNA ; Österreich
• Gesamtkosten: Keine Daten